The researchers, from Queen Mary, University of London, are testing the effectiveness of a new tablet on people who have house-dust mite induced asthma. The trial is based at Queen Mary’s William Harvey Research Institute at Charterhouse Square, one of seven trial centres in the UK.
Dr Runa Ali, Consultant Allergist at Barts and the London NHS Trust, is a Principal Investigator on the study. She said: “We need people to come forward whose asthma is set off by house-dust-mites. It will be a really exciting development if we can prove this tablet reduces their asthmatic symptoms.”
People willing to participate in the trial need to see whether they’re eligible and be able to commit to go to the clinic for 13 visits. Recruitment for the study closes on 16 December 2011.
The participants will either be required to take a house-dust mite allergy vaccine tablet or a placebo tablet once a day. Their symptoms will be measured regularly to see whether the tablet helps to reduce their asthma.
The MITRA study is expected to be finished by March 2013.
This work is sponsored by ALK-Abello, a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis.
For media information, contact:
Queen Mary, University of London